Clinical trial • Phase III • Oncology

Clinical trial in KRAS G12C-mutated non-small cell lung cancer | Non-small cell lung cancer

Phase III trial for KRAS G12C-mutated non-small cell lung cancer | Non-small cell lung cancer. 20 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
KRAS G12C-mutated non-small cell lung cancer | Non-small cell lung cancer
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
14-10-2024
First CTIS Authorization Date
25-10-2024

Trial design

Phase III trial across 2 sites in Sweden.

Target Sample Size
20

Eligibility

Recruits 20 Vulnerable population selected (isVulnerablePopulationSelected: true); no further details on consent or assent provided..

Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected: true); no further details on consent or assent provided.

Recruitment

Planned Sample Size
20
Recruitment Window Months
24

Geography

Total Number Of Sites
2
Total Number Of Participants
20

Sweden

Earliest CTIS Part Ii Submission Date
12-10-2024
Latest Decision Or Authorization Date
25-10-2024
Processing Time Days
13
Number Of Sites
2
Number Of Participants
20

Sites

Site Name
Sahlgrenska University Hospital-Vaestra Goetalandsregionen
Department Name
Oncology
Contact Person Name
Andreas Hallqvist
Contact Person Email
andreas.hallqvist@vgregion.se
Site Name
Karolinska University Hospital
Department Name
Head, Neck, Lung and Skin Cancer
Contact Person Name
Karin Lindberg

Sponsor

Primary sponsor

Full Name
Karolinska University Hospital
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Sweden

Related trials

Other published trials that may interest you.